Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
DOACs versus LMWH in Prevention of VTE Recurrence in Cancer Patients
Author(s): Patricia Noreen L Bueno , William Bernard N Ong , Frinz Moey C Rubio , et al Added: 9 months ago
Viewpoint on the 2025 ESC Guidelines for CV Disease and Pregnancy
Author(s): Ju-Le Tan Added: 1 month ago

CV Disease in Special Populations
ADA 25: PATHWEIGH: Weight Management in Primary Care
Author(s): Leigh Perreault Added: 7 months ago
ADA 25 - PATHWEIGH roadmap for implementing weight management into primary care eliminated a population weight gain trajectory.Dr Leigh Perreault (University of Colorado Anschutz Medical Campus, US) joins us remotely to discuss the PATHWEIGH trial, which investigated a process of care to facilitate and prioritize weight management in a primary care setting. PATHWEIGH focused on reducing excess… View more

Cardiovascular Renal Metabolic
Molecular Mechanisms of the Failing Heart: A Fatal Regression?
Author(s): Manami Katoh , Jin Komuro , Shunsuke Inoue , et al Added: 1 year ago

Heart Failure
CVD in Pregnancy: Challenges in Low–Middle-income Countries
Author(s): Anoosha Marium , Syed Oun Abbas , Hamna Jaskani , et al Added: 2 months ago

Guidelines & Statements

Prevention & Chronic Conditions
ECO 24: Long-Term Weight Loss in the SELECT trial
Author(s): Donna H Ryan Added: 1 year ago
ECO 2024 — Dr Donna H Ryan (Pennington Biomedical Research Center, US) joins us to discuss the first sub-analysis of the landmark SELECT trial (NCT03574597, Novo Nordisk).In this study, investigators looked at long-term weight loss with semaglutide 2.4 mg compared to a placebo among 17,604 participants. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss compared to… View more

Heart Failure

Prevention & Chronic Conditions
Weight Loss Medications: What You Need to Know in 2024
Author(s): Harold Bays Added: 1 year ago
ACC.24 — Dr Harold E Bays, Science Officer for the Obesity Medicine Association, a member of the Board of Trustees of the Obesity Medicine Association, and a member of the Board of Directors of the American Society of Preventive Cardiology, joins us to highlight key information regarding weight loss medications in 2024.Support: This is an independent interview conducted by Radcliffe Cardiology… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
ACC 2025: EVOLUT Low Risk 5Y Outcomes
Author(s): Michael J Reardon Added: 10 months ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical… View more

Intervention
TCT 23: Four-Year Outcomes from the EVOLUT Low Risk Trial
Author(s): Michael J Reardon Added: 2 years ago
TCT 23 - In this succinct interview, we are joined by Dr Michael Reardon (Houston Methodist, US) to discuss the four-year outcomes from the EVOLUT Low-Risk Trial (NCT03635424), sponsored by Medtronic. The EVOLUT Low-risk trial is a multicenter, prospective, single-arm study which aimed to assess the procedural safety and efficacy of the Medtronic TAVR system in 150 patients with bicuspid… View more

Intervention
TCT 23: 5Y Outcomes From the PARTNER 3 Low-Risk Trial
Author(s): Martin B Leon Added: 2 years ago
TCT 23 - In this short virtual interview, we are joined by Dr Martin B Leon (Columbia University Medical Center, US) to discuss the 5-year outcomes from Edwards' PARTNER 3 low-risk trial (NCT02675114).PARTNER 3 is a randomized, prospective, multicenter trial that aimed to determine the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with severe calcific aortic… View more

Intervention